SAGE Therapeutics Inc (NASDAQ:SAGE) has been given an average rating of “Buy” by the fifteen brokerages that are covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation and thirteen have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $200.58.
Several brokerages have commented on SAGE. Oppenheimer began coverage on shares of SAGE Therapeutics in a research report on Wednesday, October 10th. They set a “buy” rating and a $170.00 target price for the company. Royal Bank of Canada upped their target price on shares of SAGE Therapeutics from $259.00 to $261.00 and gave the company an “outperform” rating in a research report on Monday, November 5th. BidaskClub upgraded shares of SAGE Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday. LADENBURG THALM/SH SH set a $210.00 target price on shares of SAGE Therapeutics and gave the company a “buy” rating in a research report on Tuesday, December 11th. Finally, Morgan Stanley upped their target price on shares of SAGE Therapeutics from $228.00 to $230.00 and gave the company an “overweight” rating in a research report on Thursday, October 11th.
Shares of SAGE Therapeutics stock traded down $1.12 on Friday, hitting $125.10. 449,127 shares of the company’s stock traded hands, compared to its average volume of 1,318,216. The stock has a market capitalization of $5.62 billion, a price-to-earnings ratio of -17.64 and a beta of 2.62. SAGE Therapeutics has a one year low of $79.88 and a one year high of $195.97.
Several institutional investors and hedge funds have recently added to or reduced their stakes in SAGE. Franklin Resources Inc. increased its position in shares of SAGE Therapeutics by 66.3% in the 3rd quarter. Franklin Resources Inc. now owns 950,773 shares of the biopharmaceutical company’s stock valued at $134,277,000 after buying an additional 379,121 shares in the last quarter. Millennium Management LLC boosted its stake in SAGE Therapeutics by 622.4% in the 2nd quarter. Millennium Management LLC now owns 379,904 shares of the biopharmaceutical company’s stock worth $59,466,000 after purchasing an additional 327,312 shares during the period. Vanguard Group Inc. boosted its stake in SAGE Therapeutics by 6.9% in the 3rd quarter. Vanguard Group Inc. now owns 4,085,812 shares of the biopharmaceutical company’s stock worth $577,121,000 after purchasing an additional 262,990 shares during the period. Vanguard Group Inc boosted its stake in SAGE Therapeutics by 6.9% in the 3rd quarter. Vanguard Group Inc now owns 4,085,812 shares of the biopharmaceutical company’s stock worth $577,121,000 after purchasing an additional 262,990 shares during the period. Finally, Waddell & Reed Financial Inc. acquired a new position in SAGE Therapeutics in the 2nd quarter worth $34,640,000.
About SAGE Therapeutics
Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).
Recommended Story: How is the LIBOR rate calculated?
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.